Amarin ( (AMRN) ) just unveiled an update.
On April 9, 2025, Amarin announced a change in the ratio of its American Depositary Shares (ADS) to ordinary shares, effective April 11, 2025, to maintain its Nasdaq listing. This adjustment, resulting in a one-for-twenty reverse split of ADSs, aims to increase the per-share market price to meet Nasdaq’s minimum bid requirement, although the company cannot guarantee the expected price increase.
Spark’s Take on AMRN Stock
According to Spark, TipRanks’ AI Analyst, AMRN is a Neutral.
Amarin faces significant financial and market challenges. Declining revenues and profitability issues weigh heavily on the score. Technical analysis reflects a bearish trend, and negative valuation metrics further detract from the stock’s appeal. While the company demonstrates a strong cash position and global expansion efforts, the impact of U.S. generic competition and increasing net losses are critical concerns.
To see Spark’s full report on AMRN stock, click here.
More about Amarin
Amarin is an innovative pharmaceutical company focused on cardiovascular disease management. The company aims to enhance scientific understanding and treatment of cardiovascular risks beyond traditional therapies, with offices in the United States, Ireland, Switzerland, and other European countries, and partners globally.
YTD Price Performance: -17.50%
Average Trading Volume: 1,484,407
Technical Sentiment Signal: Strong Buy
Current Market Cap: $167.9M
See more data about AMRN stock on TipRanks’ Stock Analysis page.